American Medical Technology Inc
$5.1M 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Spineart SA
Spineart SA reported $5,057,371.38 across General Payments, Research, and Ownership to 233 physicians and teaching hospitals across 385 transactions.
- $5.1M Top quartile payer
- All-tracks total
- 385 Above-median volume
- Transactions
- 233 Above-median reach
- Recipients
- +$52.3K
- General Payments vs PY2023
Spineart SA reported $5,057,371.38 across all CMS Open Payments tracks (General + Research + Ownership) to 233 physicians and teaching hospitals in Program Year 2024 - ranking #276 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,977,821.20, averaging $21.7K per recipient.
How Spineart SA's $5.1M all-tracks total breaks down
Spineart SA's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
30/100
Total payments
D
57/100
Transaction volume
F
13/100
Physician reach
F
12/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer spineart-sa Spineart SA
$5.1M · #276/1,925 · 0.0% industry · PY2024
- TOT $5.1M
- RANK #276
- SHARE 0.0%
- TXN 385
- RCP 233
- CAT 3
- GEN $2.0M
- ΔGEN +$52.3K
- TOP1 16.9%
- PY 2024
Volume peers
Nearest volume peer: American Medical Technology Inc ($5.1M)
Spineart SA sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Spineart SA's CMS-reported General Payments increased by $52.3K (+2.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SPINEART SAPY2023: SPINEART SAPY2024: SPINEART SA. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,925,527.00
- PY2024
- $1,977,821.20
What the Data Shows for Spineart SA
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Spineart SA, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
144 transactions worth $2.0M make "Royalty or License" the top general-payment category in the 3-category breakdown below, 99.1% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Royalty or License" leads Spineart SA's 3-category general-payment breakdown at $2.0M, 99.1% of the reported total.
How Spineart SA divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $2.0M | 144 | 99.1% |
| Travel and Lodging | $15.7K | 51 | 0.8% |
| Food and Beverage | $2.5K | 38 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,028,691.12 (52.0%) of $1,977,821.20 in this company's General Payments records across 68 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Spineart SA
The five named recipients with the highest reported General Payments from this company
- 1
Alan Daniels
$335,013.82 across 7 reported transactions
- 2
Stacey Bederman
$258,846.00 across 6 reported transactions
- 3
Jeffrey Deckey
$167,176.00 across 6 reported transactions
- 4
Connor Telles
$149,765.00 across 11 reported transactions
- 5
Warren Yu
$117,890.30 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Spineart SA ranks #276 of 1,925 by total payments (top 14% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,136 of 1,838 by HHI (bottom 38% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Cosa Medical, Llc : $4.3K total payments, HHI 782
- Gen-Probe, Inc. : $641.0K total payments, HHI 781
- Ceribell, Inc. : $1.9M total payments, HHI 781
- Shofu Dental Corp : $101.9K total payments, HHI 777
- G Medical Diagnostic Services, Inc. : $1.5K total payments, HHI 776
- Spine Wave, Inc. : $326.4K total payments, HHI 775
- Spineart SA (this company) : $2.0M total payments, HHI 775
- Theratechnologies Inc. : $330.9K total payments, HHI 772
- LEO Pharma AS : $192.0K total payments, HHI 771
- Axonics, Inc. : $3.0M total payments, HHI 767
- Veracyte, Inc. : $1.3K total payments, HHI 765
- Fosun Pharma USA Inc. : $42.7K total payments, HHI 763
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Spineart SA's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Spineart SA.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Spineart SA.
Showing 6 of 1,924 companies with CMS-reported payment data.
Jcbd, LLC
$5.1M 10 recipients
Compare payment profiles
ADC Therapeutics America, Inc.
$5.1M 4,269 recipients
Compare payment profiles
Nevro Corp.
$5.0M 30,803 recipients
Compare payment profiles
BrainScope Company, Inc.
$5.1M 25 recipients
Compare payment profiles
Pristine Surgical LLC
$5.1M 5 recipients
Compare payment profiles
Put this to use
Spineart SA ranks #276 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where Spineart SA sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Spineart SA. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.